Jordan

Reimbursed Care Access

Jordan maintains a highly restrictive national drug control regime: most classical psychedelics (psilocybin, MDMA, DMT, mescaline, 5‑MeO‑DMT, ibogaine, ayahuasca, 2C‑X) are treated as controlled/psychotropic substances with criminal penalties and no routine medical reimbursement or authorized clinical treatment access. Ketamine is used within Jordanian healthcare primarily as an anaesthetic in hospitals (medical use), but psychedelic or psychiatric uses are off‑label and not publicly reimbursed; esketamine (Spravato) has no public record of local marketing authorisation or reimbursement. Clinical research activity in Jordan involving ketamine and other substances exists but access outside approved trials is effectively prohibited by the national drugs law and enforcement practice.